Core Viewpoint - *ST Huicheng has selected Zhi'en Biotechnology as the restructuring investor during its pre-restructuring phase, but no formal agreement has been signed yet, leaving future collaboration uncertain [1][2] Group 1: Company Developments - *ST Huicheng has experienced a stock price increase of 15.83% over three consecutive trading days, followed by a decline of 4.95% on the latest trading day, closing at 4.80 yuan [1] - The company has initiated the recruitment of restructuring investors since August 9, with three potential investors meeting the requirements and submitting their materials [1] - Zhi'en Biotechnology was selected as the restructuring investor based on a comprehensive evaluation of submitted restructuring investment proposals [1][2] Group 2: Zhi'en Biotechnology Overview - Zhi'en Biotechnology, established in April 2001, focuses on building a drug lifecycle management service system and holds various qualifications, including being a national high-tech enterprise [2] - The company has over 50 products, including key medications such as orlistat capsules for weight loss and donepezil hydrochloride tablets for Alzheimer's disease [2][3] - Zhi'en Biotechnology is the largest global supplier of orlistat, having achieved full synthetic industrial production of the active pharmaceutical ingredient [3] Group 3: Previous Collaborations - Prior to the restructuring investment selection, *ST Huicheng and Zhi'en Biotechnology had collaborated, with *ST Huicheng acquiring a 51% stake in Chongqing Rui'en Pharmaceutical for 47 million yuan [4] - The biopharmaceutical business, including Rui'en Pharmaceutical, has become a significant revenue contributor for *ST Huicheng, accounting for 57.41% of its revenue in the first half of the year [4] - Rui'en Pharmaceutical reported a revenue of 122 million yuan and a net profit of 23.44 million yuan in the first half of the year [4]

Group 1 - The company announced that its wholly-owned subsidiary, Baoding Tianhao Pharmaceutical Co., Ltd., received approval from the Hebei Provincial Drug Administration for changes in the production scope and entrusted production situation of its Drug Production License [1] - The production license includes various forms of medications such as ointments, tablets, solutions, and capsules, with the license valid until July 7, 2030 [1] - Changes in production lines include specific formulations such as "Oseltamivir Phosphate Oral Suspension" and "Donepezil Hydrochloride Tablets" [2][3] Group 2 - Baoding Tianhao Pharmaceutical Co., Ltd. has entrusted Shandong Buchang Pharmaceutical Co., Ltd. to produce Donepezil Hydrochloride Tablets, with the entrusted production valid until July 7, 2030 [3] - The changes in the Drug Production License are expected to optimize the production structure and maintain stable production capacity, positively impacting the company's future operations [4]

Core Viewpoint - The announcement highlights the approval of changes to the drug production license of Baoding Tianhao Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Shandong Buchang Pharmaceutical Co., Ltd., which is expected to optimize production structure and maintain stable production capacity to meet market demand [1][4]. Summary by Sections Drug Production License Information - Baoding Tianhao Pharmaceutical Co., Ltd. has received permission from the Hebei Provincial Drug Administration to change the production scope and drug commissioning details of its drug production license [1]. - The production address is located at 128 Xinghua East Road, Dingxing County, Hebei Province, and the license is valid until July 7, 2030 [1]. Changes in Production Lines - The production line at Tianjin Hanrui Pharmaceutical Co., Ltd. has changed from "oral suspension" to "oral suspension (Oseltamivir phosphate dry suspension)" [2]. - The production line at Shandong Buchang Pharmaceutical Co., Ltd. has changed from "tablets" to "tablets (Donepezil hydrochloride tablets)" [2]. - The production line at Yangling Buchang Pharmaceutical Co., Ltd. has changed from "tablets" to "tablets (Sitagliptin and Metformin sustained-release tablets), tablets (Compound Sodium Sulfate tablets)" [2]. Commissioning Details - Baoding Tianhao Pharmaceutical Co., Ltd. has commissioned Shandong Buchang Pharmaceutical Co., Ltd. to produce Donepezil hydrochloride tablets, with the production address at 1566 Zhonghua West Road, Heze City, and the commissioning is valid until July 7, 2030 [3]. Impact on Future Operations - The changes in the drug production license are expected to positively impact the company's future operations by optimizing production structure and ensuring stable production capacity to meet market demand [4].

Core Viewpoint - The announcement indicates that Harbin Zhenbao Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Zhenbao Island (603567), has received approval from the National Medical Products Administration for the transfer of marketing authorization for ten drugs from Anhui Jiuzhou Fangyuan Pharmaceutical Co., Ltd. to Harbin Zhenbao Pharmaceutical Co., Ltd. This change is not expected to have a significant impact on the company's current operating performance [1]. Group 1 - The approval includes the transfer of marketing authorization for ten drugs, which are Olanzapine Tablets, Apixaban Tablets, Escitalopram Oxalate Tablets, Desloratadine Tablets, Voriconazole Tablets, Mecobalamin Tablets, Rivaroxaban Tablets, Valsartan Tablets, and Donepezil Hydrochloride Tablets [1]. - The change in marketing authorization holders is a strategic move for Harbin Zhenbao Pharmaceutical Co., Ltd. to consolidate its product portfolio [1]. - The company emphasizes that this regulatory approval will not materially affect its current financial performance [1].